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The American College of Cardiology (ACC)/AmericanHeart Association (AHA) Task Force on Practice Guide-
lines regularly reviews existing guidelines to determine when
an update or a full revision is needed. This process gives
priority to areas in which major changes in text, and partic-
ularly recommendations, are merited on the basis of new
understanding or evidence. Minor changes in verbiage and
references are discouraged.
The ACC/AHA/American College of Physicians–American
Society of Internal Medicine (ACP-ASIM) Guidelines for the
Management of Patients With Chronic Stable Angina, which
were published in June 1999, have now been updated. The
full-text guideline incorporating the updated material is available
on the Internet (www.acc.org or www.americanheart.org) in
both a track-changes version showing the changes in the 1999
guideline in strike-out (deleted text) and highlighting (new text)
and a “clean” version that fully incorporates all the changes.
This summary article describes the 4 most important areas
of change reflected in the update in a format that we hope can
be read and understood as a stand-alone document. Interested
readers are referred to the full-length version on the Internet
to completely understand the location of these changes within
the full-length guideline, as well as their proper context. The
full-length guideline includes some additional changes that
are not reflected in this summary article. All new references
appear in bold-faced type; all original references appear in
normal type.
Although the primary focus of this guideline is on symp-
tomatic patients, asymptomatic patients with known or sus-
pected coronary disease are included in this update and are
described in Section V.
The customary ACC/AHA classifications I, IIa, IIb, and III
and the corresponding levels of evidence are used throughout
the document.
Class I: Conditions for which there is evidence or
general agreement that a given procedure
or treatment is useful and effective.
Class II: Conditions for which there is conflicting
evidence or a divergence of opinion about
the usefulness/efficacy of a procedure or
treatment.
Class IIa: Weight of evidence/opinion is in favor of
usefulness/efficacy.
Class IIb: Usefulness/efficacy is less well estab-
lished by evidence/opinion.
Class III: Conditions for which there is evidence
and/or general agreement that the pro-
cedure/treatment is not useful/effective
and in some cases may be harmful.
Level of Evidence A: Data derived from multiple random-
ized clinical trials.
Level of Evidence B: Data derived from a single random-
ized trial or nonrandomized studies.
Level of Evidence C: Consensus opinion of experts.
The ACC/AHA Task Force on Practice Guidelines wel-
comes feedback on this update process and the format of this
article. Please direct your comments to the Task Force in care
of Dawn Phoubandith, American College of Cardiology, or
via e-mail (dphouban@acc.org).
II. Angiotensin Converting Enzyme Inhibitors
New Recommendations for Angiotensin
Converting Enzyme (ACE) Inhibitors
Class I
1. ACE inhibitor in all patients with coronary artery
disease (CAD)* who also have diabetes and/or left
ventricular systolic dysfunction. (Level of Evidence: A)
Class IIa
1. ACE inhibitor in patients with CAD* or other
vascular disease. (Level of Evidence: B)
*Significant CAD by angiography or previous myocar-
dial infarction.
The results of the Heart Outcomes Prevention Evaluation
(HOPE) trial now confirm that use of the ACE inhibitor
ramipril (10 mg/d) reduced the incidence of cardiovascular
death, myocardial infarction (MI), and stroke in patients who
were at high risk for, or had, vascular disease in the absence
of heart failure (1). The primary outcome in HOPE was a
composite of cardiovascular death, MI, and stroke. However,
the results of HOPE were so definitive that each of the
components of the primary outcome by itself also showed
statistical significance. Furthermore, only a small part of the
benefit could be attributed to a reduction in blood pressure
(2 to 3 mm Hg).
The results of HOPE were extremely impressive when one
considers the magnitude of the difference between ramipril
and placebo in the primary outcomes of cardiovascular death,
MI, and stroke. The HOPE study was unique in that of the
9541 patients in the study, 3577 (37.5%) had diabetes. There
was a very significant reduction in diabetic complications, a
composite for the development of diabetic nephropathy, need
for renal dialysis, and laser therapy for diabetic retinopathy,
in those patients receiving ramipril. Even more fascinating
was the finding that among the patients who were not
designated as diabetic at the beginning of the trial, fewer were
diagnosed with diabetes during the 4-year observation period
if they were treated with ramipril. Before the HOPE trial,
numerous clinical trials suggested that ACE inhibitor treat-
ment may delay or prevent cardiovascular outcomes in
patients with diabetes after an MI, in the presence of
hypertension, and in the presence of a low ejection fraction or
heart failure. Furthermore, ACE inhibitors may also prevent
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overt nephropathy and other microvascular outcomes in
patients with type 1 or type 2 diabetes.
The Microalbuminuria, Cardiovascular, and Renal Out-
comes (MICRO)-HOPE study, a substudy of the HOPE
study, has provided new clinical data on the cardiorenal
therapeutic benefits of ACE inhibitor intervention in a broad
range of middle-aged patients with diabetes mellitus who are
at high risk for cardiovascular events. The risk of MI was
reduced by 22% (P0.01), stroke by 33% (P0.0074),
cardiovascular death by 37% (P0.0001), and the combined
primary outcome of these events by 25% (P0.0004).
Ramipril also lowered the risk of overt nephropathy by 24%
(P0.027).
ACE inhibitors should be used in most cases as routine
secondary prevention for patients with known CAD, partic-
ularly in diabetics without severe renal disease. There are 2
ongoing clinical trials evaluating the effect of 2 different
ACE inhibitors in patient populations that do not include
patients with diabetes mellitus. These studies will answer the
question whether a vasculoprotective effect can be accom-
plished in a lower-risk group of patients than those enrolled in
the HOPE study.
III. Treatment of Risk Factors
New/Changed Recommendations†
Class IIa
1. In patients with documented or suspected CAD and
low-density lipoprotein (LDL) cholesterol 100 to 129
mg/dL, several therapeutic options are available:
(Level of Evidence: B)
a. Lifestyle and/or drug therapies to lower LDL to
less than 100 mg/dL. (Level of Evidence: B)
b. Weight reduction and increased physical activity
in persons with the metabolic syndrome. (Level of
Evidence: B)
c. Institution of treatment of other lipid or nonlipid
risk factors; consider use of nicotinic acid or
fibric acid for elevated triglycerides or low high-
density lipoprotein (HDL) cholesterol. (Level of Ev-
idence: B)
2. Therapy to lower non-HDL cholesterol in patients with
documented or suspected CAD and triglyceride levels
greater than 200 mg/dL, with a target non-HDL choles-
terol level of less than 130 mg/dL. (Level of Evidence: B)
3. Weight reduction in obese patients in the absence of
hypertension, hyperlipidemia, or diabetes mellitus. (Level
of Evidence: C)
Class III
1. Initiation of hormone replacement therapy (HRT)
in postmenopausal women for the purpose of reduc-
ing cardiovascular risk. (Level of Evidence: A)
2. Vitamin C and E supplementation. (Level of Evi-
dence: A)
3. Coenzyme Q. (Level of Evidence: C)
†The original recommendations, and particularly the 6
Class I recommendations, continue to apply.
Many of the new recommendations reflect the latest
recommendations of the National Cholesterol Education Pro-
gram–Adult Treatment Panel III (ATP-III) (2), which the
writing committee strongly endorses.
The results of the largest cholesterol-lowering trial yet
performed, the Heart Protection Study (HPS), were published
as this update was in the final stages of preparation (2a). This
trial included more than 20 000 men and women age 40 to 80
years with coronary disease, other vascular disease, diabetes,
and/or hypertension. Patients were randomized to simvastatin
40 mg or matching placebo and were followed for a mean of
five years. The primary end point, total mortality, was
reduced by statin treatment by approximately 25% overall
and similarly in all important prespecified subgroups, includ-
ing: women, patients more than 75 years old, diabetics, and
individuals with baseline LDL cholesterol of less than 100
mg per dL. Analysis of these data by all appropriate author-
ities, including the National Cholesterol Education project,
will be necessary to clarify their implications for these
guidelines.
A. LDL Cholesterol
The clinical trial data indicate that in patients with established
coronary disease, including chronic stable angina pectoris,
dietary intervention and treatment with lipid-lowering medi-
cations should not be limited to those with extreme values.
The benefits of lipid-lowering therapy were evident in pa-
tients in the lowest baseline quartile of LDL cholesterol
(modest elevations) in the Scandinavian Simvastatin Survival
Study (4S) and in those with minimal elevation of LDL
cholesterol level in the Cholesterol And Recurrent Events
(CARE) study. These trials establish the benefits of aggres-
sive lipid-lowering treatment for most patients with coronary
disease, even when LDL cholesterol is within a range
considered acceptable for patients in a primary prevention
setting. For patients with established coronary disease, non-
pharmaceutical treatment and drug treatment are warranted in
the vast majority of patients. The goal of treatment is an LDL
cholesterol level less than 100 mg/dL. When LDL cholesterol
is 101 to 129 mg/dL, either at baseline or with LDL-lowering
therapy, several therapeutic options are available:
● Initiate or intensify lifestyle and/or drug therapies specifi-
cally to lower LDL.
● Emphasize weight reduction and increased physical activ-
ity in persons with the metabolic syndrome (see below).
● Delay use or intensification of LDL-lowering therapies and
institute treatment of other lipid or nonlipid risk factors;
consider use of other lipid-modifying drugs (eg, nicotinic
acid or fibric acid) if the patient has elevated triglyceride or
low HDL cholesterol levels.
B. Non-HDL Cholesterol
The finding that elevated triglycerides are an independent risk
factor for coronary heart disease (CHD) suggests that some
triglyceride-rich lipoproteins are atherogenic. The latter are
partially degraded very-low-density lipoproteins (VLDL),
commonly called “remnant lipoproteins.” In clinical practice,
non-HDL cholesterol is the most readily available measure of
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the total pool of atherogenic lipoproteins, including remnants.
Thus, non-HDL cholesterol can be a target of cholesterol-
lowering therapy. Moreover, non-HDL cholesterol is highly
correlated with total apolipoprotein B (apoB) (3,4); apoB is
the major apolipoprotein of all atherogenic lipoproteins.
Serum total apoB also has been shown to have a strong
predictive power for severity of coronary atherosclerosis and
CHD events (5–12). Because of the high correlation between
non-HDL cholesterol and apoB levels (3,4), non-HDL cho-
lesterol represents an acceptable surrogate marker for total
apoB; the latter is not widely available for routine measure-
ment in clinical practice. Therefore, ATP III (2) identifies the
sum of LDL and VLDL cholesterol (termed “non-HDL
cholesterol” [total cholesterol minus HDL cholesterol]) as a
secondary target of therapy in persons with high triglycerides
(greater than 200 mg/dL). The goal for non-HDL cholesterol
(for persons with serum triglycerides greater than or equal to
200) is 130 mg/dL; this is 30 mg/dL higher than the goal for
LDL cholesterol, because the normal VLDL cholesterol level
is 30 mg/dL.
C. HDL Cholesterol
ATP III has defined a low HDL cholesterol level as less than
40 mg/dL (2). Patients with established coronary disease and
low HDL cholesterol are at high risk for recurrent events and
should be targeted for aggressive nonpharmacological treat-
ment (dietary modification, weight loss, and/or physical
exercise). ATP III does not specify a goal for HDL raising.
Although clinical trial results suggest that raising HDL will
reduce risk, the evidence is insufficient to specify a goal of
therapy. Furthermore, currently available drugs do not ro-
bustly raise HDL cholesterol. A low HDL level should
receive clinical attention and management according to the
following sequence. In all persons with low HDL cholesterol,
the primary target of therapy is LDL cholesterol; ATP III
guidelines for diet, exercise, and drug therapy should be
followed to achieve the LDL cholesterol goal. Second, after
the LDL goal has been reached, emphasis shifts to other
issues. When a low HDL cholesterol level is associated with
high triglycerides (200 to 499 mg/dL) secondary priority goes
to achieving the non-HDL cholesterol goal, as outlined
earlier. Also, if triglycerides are less than 200 mg/dL (isolated
low HDL cholesterol), drugs to raise HDL (fibrates or
nicotinic acid) can be considered. Nicotinic acid and fibrates
usually raise HDL levels, as do 3-hydroxy-3-methylglutaryl
coenzyme A (HMG-CoA) reductase inhibitors.
D. Triglycerides
Triglyceride levels are predictive of CHD risk in a variety of
observational studies and clinical settings (13). Much of the
association of triglycerides with CHD risk is related to other
factors, including diabetes, obesity, hypertension, high LDL
cholesterol, and low HDL cholesterol (14). In addition,
hypertriglyceridemia is often found in association with ab-
normalities in hemostatic factors (15). Recently, however, a
borderline (150 to 199 mg/dL) or high (greater than 200
mg/dL) triglyceride level has been established by meta-anal-
yses of prospective studies as an independent risk factor for
CHD (2,16,17).
Nonpharmacological management of high triglycerides
consists of weight loss, reduction in alcohol consumption for
those in whom this mechanism may be causal, smoking
cessation, and physical activity. Drugs that can lower triglyc-
erides include nicotinic acid, fibrate derivatives, and, to a
lesser degree, statins. It is not clear whether treatment
directed at high triglyceride levels will reduce risk for initial
or recurrent CHD events. Also, triglyceride measurements
vary considerably for individual patients. Accordingly, the
ATP III (2) provides guidance for the management of
elevated triglyceride levels by focusing on a combination of
therapeutic lifestyle changes and by a secondary lipid target
for non-HDL cholesterol.
E. Obesity
Obesity is a common condition associated with increased risk
for coronary disease and mortality (18). Obesity is defined as
a body mass index (weight in kilograms divided by the square
of height in meters) of 30 kg/m2, and overweight begins at 25
kg/m2 (19). Obesity is associated with and contributes to other
coronary disease risk factors, including high blood pressure,
glucose intolerance, low HDL cholesterol, and elevated
triglyceride levels. Hence, much of the increased CAD risk
associated with obesity is mediated by these risk factors. Risk
is particularly raised in the presence of abdominal obesity,
which can be identified by a waist circumference greater than
102 cm (40 inches) in men or 88 cm (35 inches) in women
(19). Because weight reduction in overweight and obese
people is a method to reduce multiple other risk factors, it is
an important component of secondary prevention of CHD.
F. Metabolic Syndrome
Evidence is accumulating that risk for future CHD events can
be reduced beyond that achieved by LDL-lowering therapy
by modification of a specific secondary target of therapy—
the metabolic syndrome—represented by a constellation of
lipid and nonlipid risk factors of metabolic origin. This
syndrome is closely linked to a generalized metabolic disor-
der called insulin resistance in which the normal actions of
insulin are impaired. Excess body fat (particularly abdominal
obesity) and physical inactivity promote the development of
insulin resistance, but some individuals also are genetically
predisposed to insulin resistance. In a field that has been
confused by nomenclature, ATP III has introduced a standard
definition for the diagnosis of the metabolic syndrome, as
shown in the Table. The metabolic syndrome is considered to
be present when 3 or more of the characteristics are present.
Management of the metabolic syndrome has a 2-fold
objective: (1) to reduce underlying causes (ie, obesity and
physical inactivity) and (2) to treat associated nonlipid and
lipid risk factors. First-line therapies for all lipid and nonlipid
risk factors associated with the metabolic syndrome are weight
reduction and increased physical activity, as well as appropriate
control of LDL cholesterol. In patients with triglycerides greater
than 200 mg/dL, a non-HDL cholesterol goal of less than 130
mg/dL is a secondary target (see the Table).
G. Hormone Replacement Therapy
On the basis of epidemiological studies and prospective
studies of the effects of estrogen administration on cardiac
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risk factors, postmenopausal estrogen replacement has been
advocated for both primary and secondary prevention of
CAD in women. However, the first published randomized
trial of estrogen plus progestin therapy in postmenopausal
women with known CAD did not show any reduction in
cardiovascular events over 4 years of follow-up (20), despite
an 11% lower LDL cholesterol level and a 10% higher HDL
cholesterol level in those women receiving HRT. In addition,
women receiving HRT had higher rates of cardiovascular
events during the first 2 years, more thromboembolic events,
and more gallbladder disease (20). A subsequent angio-
graphic study also revealed no benefit from HRT (21).
Another prospective randomized controlled trial with HRT in
women with a history of stroke found no benefit in reducing
mortality or stroke after 2.8 years (22). The Women’s Health
Initiative, a randomized controlled primary prevention trial of
estrogen plus progestin, found that the overall health risks of
this therapy exceeded its benefits (23). Thus, current infor-
mation suggests that HRT in postmenopausal women does
not reduce risk for major vascular events or coronary deaths
in secondary prevention. Women who are taking HRT and
who have vascular disease can continue this therapy if it is
being prescribed for other well-established indications and no
better alternative therapies are appropriate. However, at the
present time, there is no basis for adding or continuing
estrogens in postmenopausal women with clinically evident
CAD or cerebrovascular disease in an effort to prevent or
retard progression of their underlying disease (24).
If a woman develops an acute CAD event while undergo-
ing HRT, it is prudent to consider discontinuance of the HRT
(24). In women who are immobilized, HRT should be
discontinued, or venous thromboembolism prophylaxis
should be used (24).
H. Oxidative Stress
Evidence from clinical trials is negative regarding the effects
of supplementation with antioxidant vitamins. Although sev-
eral small trials and in vitro data from basic research in
vascular biology have suggested that vitamin C and/or E
might interfere with formation of atherosclerotic lesions, 2
large randomized clinical trials have shown no benefit when
vitamin E was given to post-MI patients (25) or in those with
vascular disease or diabetics with a high-risk CAD profile
(26–28). Furthermore, a small coronary regression trial, the
HDL Atherosclerosis Treatment Study (HATS), suggested an
adverse effect of antioxidant vitamins on coronary atheroscle-
rosis, clinical events, and HDL and apoA-1 metabolism
(27,28). The use of vitamin E (administered with vitamin C
and beta-carotene) was the subject of a large (more than 20
000 participants) trial of patients at risk for CAD and with
CAD (26). Antioxidant therapy had no effect on the end
points of cardiovascular death, cardiovascular events, stroke,
or revascularization, considered alone or in combination.
Although previous observational and epidemiological studies
have suggested a benefit from dietary supplementation with
antioxidants or a diet rich in antioxidants, especially vitamin
E, there is currently no basis for recommending that patients
take vitamin C or E supplements or other antioxidants for the
express purpose of preventing or treating CAD.
IV. Alternative Therapies for Chronic Stable
Angina in Patients Refractory to Medical





1. Surgical laser transmyocardial
revascularization (TMR). (Level of Evidence: A)
Class IIb
1. Enhanced external counterpulsation (EECP).
(Level of Evidence: B)
2. Spinal cord stimulation (SCS). (Level of
Evidence: B)
Evidence has emerged regarding the relative efficacy, or
lack thereof, of a number of techniques for the management
of refractory chronic angina pectoris. These techniques
should only be used in patients who cannot be managed
adequately by medical therapy and who are not candidates for
revascularization (interventional and/or surgical).
A. Spinal Cord Stimulation
Since approximately 1987, SCS has been proposed as a
method for providing analgesia for patients with chronic
angina pectoris refractory to medical, catheter interventional,
or surgical therapy. The efficacy of SCS depends on the
accurate placement of the stimulating electrode in the dorsal
epidural space, usually at the C7-T1 level. A review of the
literature has revealed 2 small randomized clinical trials
involving implanted spinal cord stimulators, 1 of which
directly tested its efficacy. One report studied the efficacy of
SCS in 13 treated patients versus 12 control subjects, both
groups with chronic intractable angina pectoris studied for 6
weeks (29). Another small randomized trial involved 24
patients with refractory angina (30). Nine other studies, either
retrospective (31–33) or prospective (29,34–38) cohort stud-
ies, were identified in the literature. Although the results of
these studies appear promising, there is still a paucity of data
on the intermediate- and long-term benefit of these devices.
Characteristics Used to Define Metabolic Syndrome
Risk Factor Defining Level
Abdominal obesity Waist circumference
Men Greater than 103 cm (40 in)
Women Greater than 88 cm (35 in)
Triglycerides Greater than 150 mg/dL
HDL cholesterol
Men Less than 40 mg/dL
Women Less than 50 mg/dL
Blood pressure Greater than or equal to 130/85 mm Hg
Fasting serum glucose Greater than or equal to 110 mg/dL
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B. Enhanced External Counterpulsation
Another nonpharmacological technique that has been de-
scribed for treatment of patients with chronic stable angina is
known as EECP. EECP was evaluated in a randomized,
placebo-controlled multicenter trial to determine its safety
and efficacy (39). Patients (n139) with chronic stable
angina, documented CAD, and a positive exercise treadmill
test were randomly assigned to receive EECP (35 hours of
active counterpulsation) or inactive EECP over a 4- to 7-week
period. The authors concluded that EECP decreased angina
frequency (P0.05) and improved time to exercise-induced
ischemia (P0.01). Two multicenter registry studies that
included 978 patients from 43 centers (40) and 2289 patients
from more than 100 centers (41) evaluated the safety and
effectiveness of EECP in treating chronic stable angina.
These studies found the treatment to be generally well
tolerated and efficacious; anginal symptoms were improved
in approximately 75% to 80% of patients. However, addi-
tional clinical trial data are necessary before this technology
can be recommended definitively.
C. Laser TMR
Another emerging technique that has been studied for the
treatment of more severe chronic stable angina refractory to
medical or other therapies is laser TMR. This technique has
either been performed in the operating room (with a carbon
dioxide or holmium:YAG laser) or by a percutaneous ap-
proach with a specialized (holmium:YAG laser) catheter.
Eight prospective randomized clinical trials have been per-
formed, 2 with the percutaneous technique and the other 6
with an epicardial surgical technique (42–48). The goal in
both approaches is to create a series of transmural endomyo-
cardial channels to improve myocardial revascularization.
Percutaneous TMR technology has not been approved by the
Food and Drug Administration and should therefore be
considered an experimental therapy.
The surgical TMR technique has generally been associated
with improvement in symptoms in patients with chronic
stable angina. The mechanism for improvement in anginal
symptoms is still controversial. Possible mechanisms for this
improvement include increased myocardial perfusion, dener-
vation of the myocardium, stimulation of angiogenesis, or
perhaps some other unknown mechanism (49–51). There are
conflicting data regarding improvement in exercise capacity
(43,44,47). Despite the apparent benefit in decreasing anginal
symptoms, no definite benefit has been demonstrated in terms
of increasing myocardial perfusion (43,46,47).
There are currently no published studies to document the
long-term efficacy of surgical TMR. Nonetheless, this tech-
nique appears to provide symptomatic relief for end-stage
chronic angina in the short term. Additional follow-up studies
are necessary to evaluate procedural efficacy in patients who
have undergone surgical laser TMR alone, as well as coro-
nary bypass surgery plus TMR.
V. Asymptomatic Patients With Known or
Suspected CAD
At the direction of the Task Force, this update outlines the
approach to asymptomatic patients with known or suspected
CAD on the basis of a history and/or electrocardiographic
(ECG) evidence of previous MI, coronary angiography, or an
abnormal noninvasive test. The inclusion of asymptomatic
patients with abnormal noninvasive tests does not constitute
an endorsement of such tests for the purposes of screening but
simply acknowledges the clinical reality that such patients
often present for evaluation after such tests have been
performed. Multiple ACC/AHA guidelines and scientific
statements have discouraged the use of ambulatory monitor-
ing, treadmill testing, stress echocardiography, stress myocar-
dial perfusion imaging, and electron-beam computed tomog-
raphy (EBCT) as routine screening tests in asymptomatic
individuals.
The full-text guideline includes many subsections on
asymptomatic patients, which appear at the end of the
appropriate sections for symptomatic patients. They are
integrated here into a single summary. The recommendations
for noninvasive testing, which follow, appear in multiple
different lists of recommendations in the full-length
document.
Recommendations for Noninvasive Testing for the
Diagnosis of Obstructive CAD and Risk
Stratification in Asymptomatic Patients
Class IIb
1. Exercise ECG testing without an imaging modality
in asymptomatic patients with possible myocardial
ischemia on ambulatory ECG (AECG) monitoring
or with severe coronary calcification on EBCT in the
absence of one of the following ECG abnormalities:
a. Preexcitation (Wolff-Parkinson-White) syndrome
(Level of Evidence: C)
b. Electronically paced ventricular rhythm (Level of
Evidence: C)
c. More than 1 mm of ST depression at rest (Level of
Evidence: C)
d. Complete left bundle-branch block. (Level of Ev-
idence: C)
2. Exercise perfusion imaging or exercise echocardiog-
raphy in asymptomatic patients with possible myo-
cardial ischemia on AECG monitoring or with se-
vere coronary calcification on EBCT who are able to
exercise and have one of the following baseline ECG
abnormalities:
a. Preexcitation (Wolff-Parkinson-White) syndrome
(Level of Evidence: C)
b. More than 1 mm of ST depression at rest. (Level
of Evidence: C)
3. Adenosine or dipyridamole myocardial perfusion
imaging in patients with severe coronary calcifica-
tion on EBCT but with one of the following baseline
ECG abnormalities:
a. Electronically paced ventricular rhythm (Level of
Evidence: C)
b. Left bundle-branch block. (Level of Evidence: C)
4. Adenosine or dipyridamole myocardial perfusion
imaging or dobutamine echocardiography in pa-
tients with possible myocardial ischemia on AECG
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monitoring or with coronary calcification on EBCT
who are unable to exercise. (Level of Evidence: C)
5. Exercise myocardial perfusion imaging or exercise
echocardiography after exercise ECG testing in
asymptomatic patients with an intermediate-risk or
high-risk Duke treadmill score. (Level of Evidence: C)
6. Adenosine or dipyridamole myocardial perfusion im-
aging or dobutamine echocardiography after exercise
ECG testing in asymptomatic patients with an inade-
quate exercise ECG. (Level of Evidence: C)
Class III
1. Exercise ECG testing without an imaging modality
in asymptomatic patients with possible myocardial
ischemia on AECG monitoring or with coronary
calcification on EBCT but with the baseline ECG
abnormalities listed under Class IIb1 above. (Level
of Evidence: B)
2. Exercise ECG testing without an imaging modality
in asymptomatic patients with an established diag-
nosis of CAD owing to prior MI or coronary angiog-
raphy; however, testing can assess functional capac-
ity and prognosis. (Level of Evidence: B)
3. Exercise or dobutamine echocardiography in
asymptomatic patients with left bundle-branch
block. (Level of Evidence: C)
4. Adenosine or dipyridamole myocardial perfusion
imaging or dobutamine echocardiography in asymp-
tomatic patients who are able to exercise and who do
not have left bundle-branch block or electronically
paced ventricular rhythm. (Level of Evidence: C)
5. Exercise myocardial perfusion imaging, exercise
echocardiography, adenosine or dipyridamole myo-
cardial perfusion imaging, or dobutamine echocar-
diography after exercise ECG testing in asymptom-
atic patients with a low-risk Duke treadmill score.
(Level of Evidence: C)
The use of exercise ECG testing in asymptomatic patients
as a means of screening for CAD is discussed in detail in the
ACC/AHA Guideline Update for Exercise Testing (52).
In the absence of symptoms, AECG monitoring can reveal
transient ST-segment depression suggestive of CAD. How-
ever, as indicated in the ACC/AHA Guidelines for Ambula-
tory Electrocardiography (53), there is presently no evidence
that AECG monitoring provides reliable information con-
cerning ischemia in asymptomatic subjects without known
CAD.
In the absence of symptoms, EBCT is sometimes used as a
means of screening for CAD. However, as indicated in the
ACC/AHA Expert Consensus Document on Electron-Beam
Computed Tomography for the Diagnosis and Prognosis of
Coronary Artery Disease (54), available data are insufficient
to support recommending EBCT for this purpose to asymp-
tomatic members of the general public.
Physicians are often confronted with concerned asymptom-
atic patients with abnormal findings on AECG and EBCT.
Although the published data on this situation are scant, in the
absence of symptoms, such patients probably still have a low
pretest probability of significant CAD. A negative exercise
test result only confirms the low probability of disease, and a
positive test result may not increase the probability of disease
enough to make a clinical difference.
Stress imaging procedures (ie, either stress myocardial
perfusion imaging or stress echocardiography) are generally
not indicated as the initial stress test in most such patients.
However, in patients with resting ECG abnormalities that
preclude adequate interpretation of the exercise ECG, stress
imaging procedures are preferable to the exercise ECG. If the
baseline ECG shows preexcitation or more than 1 mm of ST
depression, exercise stress imaging procedures are preferred.
If the resting ECG shows a ventricularly paced rhythm or left
bundle-branch block, vasodilator perfusion imaging is pre-
ferred. In patients who are unable to exercise, pharmacolog-
ical stress imaging is preferable to exercise ECG testing. The
preference for stress imaging under these circumstances is
based on the available literature in symptomatic patients.
There are scant published data on the use of stress imaging
procedures in asymptomatic patients in general and in partic-
ular on asymptomatic patients with resting ECG abnormali-
ties or asymptomatic patients who are unable to exercise. In
asymptomatic patients with an intermediate-risk or high-risk
Duke treadmill score on exercise ECG testing, stress imaging
procedures are potentially useful as a second diagnostic test.
Given the low pretest probability of asymptomatic patients,
an abnormal exercise ECG in such a patient is likely a
false-positive that will be confirmed by a negative stress
image. However, the published data demonstrating the effi-
cacy of stress imaging procedures in these specific circum-
stances are scant. In the presence of a low-risk Duke treadmill
score on exercise ECG testing, stress imaging procedures in
asymptomatic patients are usually not justified.
In asymptomatic patients, risk stratification and prognosis
are more important considerations than diagnosis. Because
the treatment of asymptomatic patients cannot improve their
symptoms, the principal goal of evaluation and treatment is
the improvement of patient outcome by reducing the rate of
death and nonfatal MI. In one large study dominated by
asymptomatic patients (55), the Duke treadmill score pre-
dicted subsequent cardiac events. However, the absolute
event rate was low, even in patients with high-risk scores,
which suggests that the ability to improve outcome with
revascularization in such patients is limited.
The prognostic value of stress imaging procedures in
asymptomatic patients is not well established. Some of the
published series did include asymptomatic patients. However,
this subset of patients was generally not analyzed separately.
Blumenthal et al (56) reported a small study using exercise
thallium testing in siblings of patients with premature coro-
nary atherosclerosis. They demonstrated that the combination
of an abnormal exercise ECG and a positive thallium image
was prognostically important. However, many of the events
included in their analysis were subsequent revascularizations,
the performance of which was clearly influenced by the
results of the exercise thallium test. Given the generally low
event rate in asymptomatic patients, the ability of stress
imaging procedures to identify a subset with a substantial
absolute risk of subsequent events is problematic, with the
possible exception of patients with previous MI.
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Recommendations for Coronary Angiography for
Risk Stratification in Asymptomatic Patients
Class IIa
1. Patients with high-risk criteria that suggest ischemia
on noninvasive testing. (Level of Evidence: C)
Class IIb
1. Patients with inadequate prognostic information af-
ter noninvasive testing. (Level of Evidence: C)
Class III
1. Patients who prefer to avoid revascularization. (Lev-
el of Evidence: C)
The noninvasive test findings that identify high-risk pa-
tients are based on studies in symptomatic patients. These
findings are probably also applicable to asymptomatic pa-
tients but associated with a lower level of absolute risk in the
absence of symptoms. The mere presence of left ventricular
dysfunction in an asymptomatic patient probably does not
justify coronary angiography. However, other high-risk non-
invasive test findings that reflect myocardial ischemia, such
as a high-risk Duke treadmill score, a large stress-induced
perfusion defect, or an extensive echocardiographic wall-
motion abnormality that develops at a low heart rate, are
probably appropriate indications for coronary angiography,
although there are only limited data to support this approach.
The ability to improve outcome in such patients has not been
demonstrated.
Recommendations for Pharmacotherapy to
Prevent MI and Death in Asymptomatic Patients
Class I
1. Aspirin in the absence of contraindication in patients
with prior MI. (Level of Evidence: A)
2. Beta-blockers as initial therapy in the absence of
contraindications in patients with prior MI. (Level of
Evidence: B)
3. Lipid-lowering therapy in patients with documented
CAD and LDL cholesterol greater than 130 mg/dL,
with a target LDL of less than 100 mg/dL. (Level of
Evidence: A)
4. ACE inhibitor in patients with CAD* who also have
diabetes and/or left ventricular systolic dysfunction.
(Level of Evidence: A)
Class IIa
1. Aspirin in the absence of contraindications in pa-
tients without prior MI. (Level of Evidence: B)
2. Beta-blockers as initial therapy in the absence of
contraindications in patients without prior MI. (Lev-
el of Evidence: C)
3. Lipid-lowering therapy in patients with documented
CAD and LDL cholesterol 100 to 129 mg/dL, with a
target LDL of 100 mg/dL. (Level of Evidence: C)
4. ACE inhibitor in all patients with CAD* or other
vascular disease. (Level of Evidence: B)
*Significant CAD by angiography or previous MI.
Even in asymptomatic patients, aspirin and beta-blockers
are recommended in patients with prior MI. The data in
support of these recommendations are detailed in the ACC/AHA
Guidelines for the Management of Patients With Acute Myo-
cardial Infarction (57). In the absence of prior MI, patients with
documented CAD on the basis of noninvasive testing or coro-
nary angiography probably also benefit from aspirin, although
the data on this specific subset of patients are limited.
Several studies have investigated the potential role of
-blockers in patients with asymptomatic ischemia demon-
strated on exercise testing and/or ambulatory monitoring. The
data generally demonstrate a benefit from -blocker therapy,
but not all trials have been positive.
Lipid-lowering therapy in asymptomatic patients with doc-
umented CAD was demonstrated to decrease the rate of
adverse ischemic events in 4S (58), as well as in the CARE
study (59), as mentioned previously.
A. Treatment of Risk Factors
In asymptomatic patients with documented CAD on the basis
of noninvasive testing or coronary angiography, the treatment
of risk factors outlined above is clearly appropriate. The
recommendations for symptomatic patients should be fol-
lowed as detailed in the 1999 guideline and the update section
above.
In the absence of documented CAD, asymptomatic patients
should also undergo treatment of risk factors according to
primary prevention standards. Therapy should be directed
toward hypertension, smoking cessation, diabetes, exercise
training, and weight reduction in the presence of other risk
factors. Lipid-lowering therapy should be administered ac-
cording to the primary prevention standards outlined in the
2001 National Cholesterol Education Program guidelines.2
B. Revascularization
In asymptomatic patients, revascularization cannot improve
symptoms. The only appropriate indication for revasculariza-
tion with either percutaneous coronary intervention or coro-
nary artery bypass grafting is therefore to improve prognosis.
Most of the recommendations for revascularization that were
published in 1999 for patients with stable angina also apply to
asymptomatic patients, because their underlying rationale is
to improve prognosis. The single Class I recommendation for
revascularization in patients who have not been successfully
treated by medical therapy is an exception and obviously does
not apply to asymptomatic patients. However, the level of
evidence in support of these recommendations in asymptom-
atic patients is clearly weaker than in symptomatic patients.
Most of the available randomized trial data have focused on
symptomatic patients. Their extrapolation to asymptomatic
patients appears reasonable but is based on far more limited
evidence.
In the Coronary Artery Surgery Study Registry (60),
asymptomatic patients with left main CAD who underwent
coronary artery bypass grafting had a better outcome than
those patients treated with medical therapy, but this was not
a randomized trial. The most compelling randomized trial
data on asymptomatic patients comes from the previously
mentioned Asymptomatic Cardiac Ischemia Pilot (ACIP)
study (61,62). In patients with CAD who were either free of
angina or had well-controlled symptoms, patients randomized
to revascularization had a lower cardiac event rate than
patients who were randomized to medical management
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guided by angina or medical management guided by nonin-
vasive ischemia. The patients entered in this study, who were
required to have ischemia during ambulatory monitoring and
exercise testing, as well as significant CAD, were more likely
to have extensive CAD and prior MI. In the overall study
group, 39% of the patients had 3-vessel disease, 40% had
prior MI, 22% had prior revascularization, and 59% had
angina within the previous 6 weeks. Many of the patients
enrolled in this trial presumably came to medical attention
because of symptoms or prior MI. The degree to which the
results of ACIP can be applied to patients who have never
been symptomatic and have less severe asymptomatic CAD is
uncertain.
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